Cancer Treatment Today

Ponatinib (Iclusig, AP24534) was recently FDA approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trial. B ecasue it not only attacks the CML mutation, BCR-ABL (including the T315I that other drugs doen affect it is an attarctive candidate for personalized use in conditions

Sprycel (dasatinib) is currently in trials for various types of sarcoma. Dasatinib, a small-molecule inhibitor of Src kinase activity, is a promising cancer therapeutic agent with oral bioavailability. Currently, dasatinib is approved for use in imatinib-refractory chronic myelogenous leukemia. The FDA also granted full approval of Sprycel for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) with